


Stabilis



Voriconazole



Noms commerciaux

Candiox	Equateur
Ekomikane	Mexique
Fusitop	Chili
Vfend	Allemagne, Arabie Saoudite, Argentine, Australie, Autriche, Belgique, Canada, Chili, Colombie, Danemark, Egypte, Emirats Arabes Unis, Equateur, Espagne, Etats Unis d'Amérique, Finlande, France, Grande Bretagne, Grèce, Hongrie, Iran, Irlande, Islande, Italie, Japon, Luxembourg, Malaisie, Maroc, Mexique, Norvège, Nouvelle Zélande, Pays bas, Pologne, Portugal, Roumanie, Suède, Suisse, Tunisie, Turquie, Vénézuéla
Viradep	Chili
Vorazyr	Turquie
Vorcum	Vénézuéla
Voriole	Chili
Vorix	Turquie
Vorzole	Pérou
Zivenad	Chili



Stabilité des solutions

Container	Light	Concentration	Temp	Light Protection	Time	Stability	Warning	Reference
PVC	Green triangle	0,5 mg/ml	4-7°C	Sun with slash	11	Half moon		3087
PVC	Red diamond	0,5 mg/ml	4-7°C	Sun with slash	9	Half moon		3087
PVC	Red diamond	4 mg/ml	4°C	Question mark	15	Half moon		2111
POF	Green triangle	2 mg/ml	25°C	Sun with slash	8	Half moon		2131
POF	Green triangle	2 mg/ml	4°C	Sun with slash	8	Half moon		2131
POF	Red diamond	2 mg/ml	25°C	Sun with slash	4	Half moon		2131
POF	Red diamond	2 mg/ml	4°C	Sun with slash	6	Half moon		2131
PI	Green triangle and Red diamond	2 mg/ml	25°C	Sun	4	Checkmark		4035

		2 mg/ml	35°C		4			4035
		2 mg/ml	4°C		96			4035
	RL	0,5 mg/ml	2-8°C		13			3975



Facteur influençant la stabilité

				3566
				3566
				3087



Compatibilités

	Voriconazole : 10 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
	Voriconazole : 10 mg/ml Caffeine : 10 mg/ml		3964
	Voriconazole : 4 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
			3566
	Voriconazole : 4 mg/ml Anidulafungin : 0.5 mg/ml		1982
	Voriconazole : 2 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
	Voriconazole : 8 mg/ml Cefepime dihydrochloride : 83.3 mg/ml		4254
	Voriconazole : 2 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
	Voriconazole : 4 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
	Voriconazole : 4 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
	Voriconazole : 4 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
	Voriconazole : 4 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
	Voriconazole : 10 mg/ml Cloxacillin sodium : 100 mg/ml		3012
	Voriconazole : 4 mg/ml Doripenem : 5 mg/ml		2262
	Voriconazole : 8 mg/ml Heparin sodium : 208 UI/ml		4254
	Voriconazole : 10 mg/ml Meropenem : 50 mg/ml		4319

	Voriconazole : 10 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
	Voriconazole : 10 mg/ml Paracetamol : 10 mg/ml		4742
	Voriconazole Sodium bicarbonate : 42 mg/ml		3566
	Voriconazole : 8 mg/ml Thiamine hydrochloride : 0.2 mg/ml		4254
	Voriconazole : 3 mg/ml Vasopressin : 0.2 UI/ml		2017
	Voriconazole : 0,05>>0.5 mg/ml		4633
	Voriconazole : 10 mg/ml	RL	4603
	Voriconazole		3566



Voie d'administration



Bibliographie


	Type	Source
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2017	Revue	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2111	Revue	Cadrobbi J, Hecq JD, Lebrun C, Vanbeckbergen D, Jamart J, Galanti L. Long-term stability of voriconazole 4 mg/ml in dextrose 5% polyvinyl chloride bags at 4°C. EJHP Science 2006 ; 12, 3: 57-59.
2131	Revue	Sahraoui L, Chiadmi F, Schlatter J, Toledano A, Cisternino S, Fontan JE. Stability of voriconazole injection in 0.9% sodium chloride and 5% dextrose injections. Am J Health-Syst Pharm 2006 ; 63: 1423-1426.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocartil with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.

3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3087	Revue	Adams, A.I.H., Morimoto, L.N., Meneghini, L.Z., Bergold, A.M. Treatment of invasive fungal infections: Stability of voriconazole infusion solutions in PVC bags. BJID 2008 ; 12, 5: 400-404.
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3566	Laboratoire	Voriconazole (Vfend®) - Summary of Product characteristics. Pfizer 2013
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3975	Poster	Roche M, Simon N, Bourdon F, Dhorne C, Berneron C, Lannoy D, Odou P. Stability of 50 and 100 µg/0,1mL intraocular solutions of voriconazole at 2-8°C. EAHP congress - Cannes 2017
4035	Revue	Harmanjeet H, Zaidi S.T.R, Ming L.C, Wanandy T, Patel R.P. Physicochemical stability of voriconazole in elastomeric devices. EJHP 2017 ;0:1-5
4254	Revue	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4633	Revue	Reber E, Neyer P, Schönenberger K.A, Saxer C, Bernasconi L, Stanga Z, Huber A, Hammerer-Lercher A, Mühlebach S. Physicochemical Stability and Compatibility Testing of Voriconazole in All-in-One Parenteral Nutrition Admixtures. Pharmaceutics 2021 ; 13, 1447.
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Stabilis



























Voriconazole



Stabilité des préparations

		100 mg Vfend®	Eau ppi >> 10 ml	-20°C		85		3974
		200 mg Vfend®	Eau ppi >> 20 ml	2-6°C		30		2810
		200 mg Vfend®	Eau ppi >> 20 ml	21-27°C		30		2810
		200 mg ® = Sandoz	Isopto Tears® 0.5% >> 20 mL	4°C		28		4799
		100 mg Vfend®	Eau ppi >> 10 mL	-20°C		85		3974
		30 mg Vfend®	Chlorure de benzalkonium Eau ppi >> 3 ml	0.3 mg 2-8°C		98		3083
		60 mg Vfend®	Chlorure de benzalkonium Eau ppi >> 3 ml	0.3 mg 2-8°C		112		3083

		60 mg Vfend®	Chlorure de benzalkonium Eau ppi >> 3 ml	0.3 mg 25°C		112				3083
		60 mg Vfend®	Chlorure de benzalkonium Eau ppi >> 3 ml	0.3 mg 40°C		56				3083
		50 mg Vfend®	Eau ppi >> 5mL	-20°C		90				3561
		200 mg ® = Sandoz	Isopto Tears® 0.5% >> 20 mL	4°C		28				4799
		100 mg Vfend®	Eau ppi >> 10 mL	-20°C		85				3974
		100 mg Voriconazole Arrow®	Eau ppi >> 10 mL	2-8°C		90				4705



Facteur influençant la stabilité

	Isopto Tears®	0.5%			4799
---	---------------	------	---	---	------




Bibliographie

	Type	Source
2810	Revue	Dupuis A, Tournier N, Le Moal G, Venisse N. Preparation and stability of voriconazole eye drop solution. Antimicrob Agents Chemother 2009 ; 53, 2: 798-799.
3083	Revue	Al-Badriyeh D, Li J, Stewart K, Kong DCM, Leung L, Davies GE, Robert Fullinfaw R. Stability of extemporaneously prepared voriconazole ophthalmic solution Am J Health-Syst Pharm 2009 ; 66: 1478-1483.
3561	Revue	Amoros-Reboredo P, Bastida-Fernandez C, Guerrero-Molina L, Soy-Muner D, Lopez-Cabezas C. Stability of frozen 1% voriconazole ophthalmic solution. Am J Health-Syst Pharm 2015 ; 72:479-482
3974	Revue	Roche M, Lannoy D, Bourdon F, Dhorne C, Berneron C, Danel C, G.Fernandez, M.J,Simon N, Odou P. Stability of frozen 1% voriconazole eye drops in glass and in innovative containers. Eur J Pharm Sci 2020
4705	Revue	Khan A, Venet A, Bernadou J-M, Cresto S, Servant V, Boulestreau H, Xuereb F, Crauste-Manciet S. Stability of voriconazole 10 mg/mL ophthalmic solution during 90 days Pharmaceutical Technology in Hospital Pharmacy 2022 2022; 7(1): 20210010
4799	Poster	Perks B, Law S, Ma N. Stability of Voriconazole 10 mg/mL in IsoptoTears 0.5% stored in Glass Vials And Low Density Polyethylene Droppers at 4°C and 25°C for 28 Days. 2023

Stabilis



Voriconazole



Stabilité des préparations

		1 g ® = Accord	Excipial hydrocrème® >> 100 g	4-8°C		90		4671



Bibliographie

	Type	Source
4671	Revue	Bouchand C, Nguyen D, Secretan P-H, Vidal F, Guery R, Auvity S, Cohen J.F, Lanternier Voriconazole topical cream formulation: evidence for stability and antifungal activity. Int J Antimicrob Agents 2020 ; 56: 106083.



Dictionnaire

	Antifongique		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Polyvinyl chlorure
	Chlorure de sodium 0,9%		A l'abri de la lumière
	Jour		Glucose 5%
	Non précisée		Polyolefine
	Elastomère en polyisoprène		NaCl 0,9% ou glucose 5%
	Lumière		Heure
	Non précisé	RL	Ringer lactate
	Facteur influençant la stabilité		Solvant
	Nutrition parentérale (mélange binaire)		Provoque
	Dégradation		NaHCO ₃
	Adsorption		Compatibilités
	Molécule		Compatible
	Aucun		Incompatibilité non précisée
	Incompatible		Eau pour préparation injectable
	Nutrition parentérale (mélange ternaire)		Voie d'administration
	Perfusion intraveineuse		Bibliographie
	Collyre		Stabilité des préparations
	Origine		Excipient
	Verre		Flacon injectable
	Avec ou sans lumière		Polyéthylène
	Flacon plastique		Novelia®
	Précipitation		Forme dermique
	Tube de pommade en aluminium		Dictionnaire